Tobacco, Alcohol, Prescription medications, and other Substance use Tool (TAPS)
The TAPS Tool (Tobacco, Alcohol, Prescription medication, and other Substance use Tool) is a two-part screening and brief assessment tool that identifies unhealthy substance use in adult primary care patients. A 4-item first stage (TAPS-1) asks about past-12-month use of tobacco, alcohol, non-medical prescription medication and other drugs, and a second stage (TAPS-2) gives a 0–3 risk score for each substance used in the past 3 months.
About the TAPS Tool
Developed through a NIDA-supported research initiative, the TAPS Tool integrates a brief screener (TAPS-1) with a more detailed assessment (TAPS-2) if initial risk is identified. It assesses past-year and past-3-month use across a range of substances, including tobacco, alcohol, cannabis, cocaine, prescription stimulants, sedatives, and opioids. The tool supports SBIRT (Screening, Brief Intervention, and Referral to Treatment) workflows in busy clinical environments.
It is appropriate for use with adults aged 18 and older.
What the TAPS Tool measures
TAPS-1 includes 4 items about past 12-month use, each answered as never, less than monthly, monthly, weekly, or daily or almost daily (Gryczynski et al., 2017), covering:
- Tobacco
- Alcohol
- Prescription medications (used non-medically)
- Other drugs
If any use is reported, TAPS-2 follows with frequency-based questions for the past 3 months, asking how often each substance was used and whether use affected responsibilities or safety.
How to administer the TAPS Tool
The TAPS Tool is for adults aged 18 and older and has been validated in both interviewer-administered and electronic self-administered (myTAPS, tablet) formats, with similar diagnostic performance. In the validation study, myTAPS took a median of 4.0 minutes; 98.3% of patients found it easy to use, but 25% asked for help, more often those aged over 65 or with lower education, so clinics should be ready to offer an interviewer-administered option (Adam et al., 2019).
HiBoop implements TAPS as a two-stage experience:
- Stage 1 (TAPS-1): Rapid screen, 4–5 substance categories
- Stage 2 (TAPS-2): Triggered for substances endorsed in TAPS-1, with brief follow-up questions on use severity and impact
TAPS Tool scoring and interpretation
Each substance category produces a risk score from 0 to 3; scores are read per substance rather than as one total. In the validation study, a score of 1 or more identified problem use and 2 or more was used to identify a substance use disorder (McNeely et al., 2016). On the TAPS-1 alone, the optimal cut-points for identifying a substance use disorder were monthly or more often for tobacco and alcohol, and any reported use for illicit drugs and prescription medication misuse (Gryczynski et al., 2017).
HiBoop highlights risk levels per substance and supports clinician filtering (e.g., show all clients with opioid risk ≥2).
Psychometric properties
In 2,000 adult primary care patients at five clinics in the NIDA Clinical Trials Network, the interviewer- and self-administered versions had similar diagnostic characteristics against the modified Composite International Diagnostic Interview. For problem use (cutoff 1+), sensitivity and specificity were 0.93 and 0.87 for tobacco and 0.74 and 0.79 for alcohol; for illicit and prescription drugs, sensitivity ranged from 0.82 (marijuana) to 0.63 (sedatives) with specificity of 0.93 or higher. Sensitivity for any substance use disorder (cutoff 2+) was lower (McNeely et al., 2016).
For the TAPS-1 alone, the self-administered format identified substance use disorders with sensitivity 0.92 and specificity 0.80 for tobacco, 0.71 and 0.85 for alcohol, 0.93 and 0.85 for illicit drugs, and 0.89 and 0.91 for prescription medication misuse. Among those who denied drug use, fewer than 4% had a drug-positive oral fluid test (Gryczynski et al., 2017).
Limitations
- Screening, not diagnosis. A positive screen indicates a need for clinical evaluation; it does not diagnose a substance use disorder.
- Better for problem use than disorder. The developers concluded that further refinement is needed before the TAPS Tool can be recommended broadly for substance use disorder screening.
- Imprecise for less common drugs. Low prevalence of some drug classes gave imprecise estimates, and sensitivity was lowest for sedatives.
- Frequency alone is limited. TAPS-1 frequency responses did not discriminate well between levels of problem severity.
- Self-report. Results depend on disclosure; some patients need help completing the electronic version.
This library is an academic and clinical reference. A scale described here is not necessarily offered in HiBoop; each page says whether it is.
Bill this assessment
In the US, the Tobacco, Alcohol, Prescription medications, and other Substance use Tool (TAPS) is usually billed under these CPT codes. Payer rules vary.
Using this assessment in practice
For clinicians
Send it as a gentle check-in before the session. The score is waiting when you open the chart, and the trend builds itself.
For individuals
This page is a clinical reference, not a diagnostic tool. If you have concerns about your own symptoms, bring this information to a qualified mental health professional.
Frequently Asked Questions
Is the TAPS Tool self-report or clinician-administered?
The TAPS Tool has been validated in both self-administered (tablet/electronic) and interviewer-administered formats. The self-administered format, known as myTAPS, showed high acceptability in primary care patients, though older adults and those with lower education may benefit from interviewer support. Both formats demonstrated comparable psychometric performance in the original NIDA Clinical Trials Network validation study.
What substances does the TAPS Tool screen for?
TAPS covers four substance categories: tobacco, alcohol, prescription medications used non-medically, and other drugs (including cannabis, cocaine, stimulants, sedatives, and opioids). The TAPS-1 first-stage screener asks about past 12-month use across these categories, and the TAPS-2 follow-up component gathers frequency and impact data for any endorsed substance.
References
- 1.McNeely J, Wu LT, Subramaniam G, et al. Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care Patients. Ann Intern Med. 2016;165(10):690-699.View source
- 2.Gryczynski J, McNeely J, Wu LT, et al. Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care. J Gen Intern Med. 2017;32(9):990-996.View source
- 3.Adam A, Schwartz RP, Wu LT, et al. Electronic self-administered screening for substance use in adult primary care patients: feasibility and acceptability of the tobacco, alcohol, prescription medication, and other substance use (myTAPS) screening tool. Addict Sci Clin Pract. 2019;14(1):39.View source
Last reviewed: Jun 3, 2026
Related Assessments
Explore complementary clinical tools and screeners